Guanfacine Prolonged Release Tablets
Indication
ADHD in children and adolescents aged 6 to 17 years for whom stimulants are not suitable, not tolerated or have been shown to be ineffective
Brand:
Intuniv ®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
Background
Guanfacine (Intuniv®) 1 mg, 2 mg, 3 mg, 4 mg prolonged-release tablets
are supported for treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6–17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.
- Suitable for prescribing in primary care following recommendation or initiation by a specialist.
- Minimal monitoring required.
- Patient may need a regular review, but this would not exceed that required for other medicines routinely prescribed in primary care.
- Full prior agreement about patient’s on-going care must be reached under the shared care agreement.
Primary care prescribers are advised not to take on prescribing of these medicines unless they have been adequately informed by letter of their responsibilities with regards monitoring, side effects and interactions and are happy to take on the prescribing responsibility. A copy of locally approved shared care guidelines should accompany this letter which outlines these responsibilities. Primary care prescribers should then tell secondary care of their intentions as soon as possible by letter so that arrangements can be made for the transfer of care.
Recommendation
LSCMMG Recommendation:
Amber level 1
Reason for decision:
Shared care required